Boundless Bio, Inc.
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.36% | -6.20% | 3.92% | 18.68% | 30.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.02% | -17.69% | -13.26% | -1.39% | 9.80% |
| Operating Income | 7.02% | 17.69% | 13.26% | 1.39% | -9.80% |
| Income Before Tax | 0.59% | 14.76% | 10.96% | -1.15% | -11.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.59% | 14.76% | 10.96% | -1.15% | -11.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.59% | 14.76% | 10.96% | -1.15% | -11.55% |
| EBIT | 7.02% | 17.69% | 13.26% | 1.39% | -9.80% |
| EBITDA | 8.51% | 18.07% | 13.69% | 1.71% | -9.67% |
| EPS Basic | 1.12% | 15.42% | 82.07% | 88.25% | 91.38% |
| Normalized Basic EPS | 3.62% | 15.42% | 82.07% | 88.25% | 91.38% |
| EPS Diluted | 1.12% | 15.42% | 82.07% | 88.25% | 91.38% |
| Normalized Diluted EPS | 3.62% | 15.42% | 82.07% | 88.25% | 91.38% |
| Average Basic Shares Outstanding | 0.50% | 0.77% | 31.88% | 90.96% | 246.33% |
| Average Diluted Shares Outstanding | 0.50% | 0.77% | 31.88% | 90.96% | 246.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |